Expanded carrier screening in reproductive medicine-points to consider

Obstetrics and Gynecology

Volumn 125, Issue 3, 2015, Pages 653-662

  Edwards, Janice G ^a,b   Feldman, Gerald ^a,b   Goldberg, James ^a,b   Gregg, Anthony R ^a,b   Norton, Mary E ^a,b   Rose, Nancy C ^a,b   Schneider, Adele ^a,b   Stoll, Katie ^a,b   Wapner, Ronald ^a,b   Watson, Michael S ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b American College of Medical Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CYSTIC FIBROSIS; EXPANDED CARRIER SCREENING; FRAGILE X SYNDROME; GENE FUNCTION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE; HEALTH CARE PERSONNEL; HEMOGLOBINOPATHY; HETEROZYGOTE; HUMAN; INFORMATION PROCESSING; MEDICAL EDUCATION; MEDICAL SOCIETY; PATHOGENESIS; PATIENT EDUCATION; PATIENT SATISFACTION; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REPRODUCTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SPINAL MUSCULAR ATROPHY; TAY SACHS DISEASE; GENETIC DISEASES, INBORN; HETEROZYGOTE DETECTION; INFORMED CONSENT; MASS SCREENING; MATERNAL SERUM SCREENING TEST; MOLECULAR DIAGNOSIS; TRENDS;

GENETIC COUNSELING; GENETIC DISEASES, INBORN; HETEROZYGOTE DETECTION; HUMANS; INFORMED CONSENT; MASS SCREENING; MATERNAL SERUM SCREENING TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; REPRODUCTIVE MEDICINE;

EID: 84923584486     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000666     Document Type: Review

References (23)

1. Sherman S, Pletcher BA, Driscol DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005;7:584-7.
2. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V, Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-48.
3. U.S. Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145:204-8.
4. Hemoglobinopathies in pregnancy. ACOG Practice Bulletin No. 78. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;109:229-37.
5. Gross SJ, Pletcher BA, Monaghan KG; Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008;10:54-6.
6. Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. ACOG Committee Opinion No. 442. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114: 950-3.
7. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387-91.
8. Update on carrier screening for cystic fibrosis. Committee Opinion No. 486. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;117:1028-31.
9. Langfelder-Schwind E, Karczeki B, Strecker MN, Redman J, Sugarman E, Zaleski C, et al. Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns 2014; 23:5-15.
10. Prior TW; Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008;10:840-2.
11. Spinal muscular atrophy. ACOG Committee Opinion No. 432. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113:1194-6.
12. Carrier screening for fragile X syndrome. Committee Opinion No. 469. American College of Obstetricians and Gynecologists. Obstet Gynecol 2010;116:1008-10.
13. Finucane B, Abrams L, Cronister A, Archibald AD, Bennett RL, McConkie-Rosell A. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the National Society of Genetic Counselors. J Genet Couns 2012; 21:752-60.
14. Genetic Information Nondiscrimination Act of 2008. Pub. L. No. 110-233, 122 stat. 881. 2008.
15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm H, on behalf of the ACMG Laboratory Quality Assurance Committee. Standards and Guidelines for the Interpretation of Sequence Variants: A joint consensus recommendation from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. American College of Medical Genetics and Genomics website. Available at: https://www.acmg.net/docs/Standards-Guidelines-for-the- Interpretation-of-Sequence-Variants.pdf. Retrieved January 20, 2015.
16. Ormond KE, Iris M, Banuvar S, Minogue J, Annas GJ, Elias S. What do patients prefer: informed consent models genetic carrier testing. J Genet Couns 2007;16:539-50.
17. Cho D, McGowan ML, Metcalfe J, Sharp RR. Expanded carrier screening in reproductive healthcare: perspectives from genetic professionals. Hum Reprod 2013;28:1725-30.
18. Wienke S, Brown K, Farmer M, Strange C. Expanded carrier screening panels-does bigger mean better?. J Community Genet 2014;5:191-8.
19. Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862-77.
20. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med 2013;15:153-6.
21. Alexander J, Kowdley KV. HFE-Associated hereditary hemochromatosis. Genet Med 2009;11:307-13.
22. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-22.
23. Rossi E, Jeffrey GP. Clinical penetrance of C282Y homozygous HFE haemochromatosis. Clin Biochem Rev 2004;25:183-90.